New obesity drug combo tested for safety in 176-Person trial

NCT ID NCT06771115

Completed Disease control Sponsor: Zomagen Biosciences Ltd. Source: ClinicalTrials.gov ↗

First seen Nov 10, 2025 · Last updated Apr 30, 2026 · Updated 26 times

Summary

This study tested whether a new drug called VTX3232, taken alone or with the weight-loss drug semaglutide, is safe for people with obesity. About 176 adults with a BMI between 30 and 42 took part. The main goal was to check for side effects over 12 weeks of treatment.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Locations

840001

Largo, Florida, 33761, United States
840002

Austin, Texas, 78705, United States
840003

Lake Forest, California, 92630, United States
840005

Birmingham, Alabama, 35235, United States
840006

Dallas, Texas, 75230, United States
840010

Waco, Texas, 76710, United States
840011

Long Beach, California, 90815, United States
840012

Ocoee, Florida, 34761, United States
840013

San Antonio, Texas, 78229, United States
840014

Newton, Kansas, 67114, United States
840015

Marrero, Louisiana, 70072, United States
840016

Port Orange, Florida, 32127, United States
840017

Marrero, Louisiana, 70072, United States
840018

San Antonio, Texas, 78229, United States

Conditions

Explore the condition pages connected to this study.

OBESITY